Sam Tisherman, MD

Professor of Critical Care Medicine
  • “LY333328 versus Vancomycin in Skin/Skin-structure Infections”, Eli Lilly, University of Pittsburgh Principle Investigator, 1999-2000. Goal was to compare a new antibiotic (LY333328 to vancomycin in terms of efficacy for complicated skin infections
  • “Prophylactic Antibiotics in the Management of Tube Thoracostomy for Traumatic Hemopneumothorax (PAMOTTTH study)”, Eastern Association for the Surgery of Trauma, 1999-present. Goal is to determine if prophylactic antibiotics are beneficial for patients who require chest tubes for trauma.
  • “Novel Resuscitation from Lethal Hemorrhagic Shock”, Office of Naval Research, 2000-present. Goal is to develop novel resuscitation strategies to improve outcome from prolonged hemorrhagic shock.
  • “Novel Resuscitation from Lethal Hemorrhage. Suspended Animation for Delayed Resuscitation”, US Army-Combat Casualty Care, 2000-present. Goal is to develop a novel resuscitation strategy called suspended animation that can preserve the exsanguinated trauma victim until delayed resuscitation and surgery are possible.
  • “A Prospective, Randomized, Double-Blind, Multicenter Trial Assessing the Safety and Efficacy of Sequential (Intravenous/Oral) BAY 12-8039 (Moxifloxacin) 400 Mg every 24 hours Compared to Intravenous Piperacillin/Tazobactam 3.375 Grams every 6 Hours Followed by Oral Amoxicillin/Clavulanic Acid Suspension 800 Mg every 12 Hours for the Treatment of Patients with Complicated Intra-abdominal Infections.”, Bayer, University of Pittsburgh Principle Investigator, 2000-present. Goal is compare a new quinolone with standard antibiotics for the treatment of patients with complicated intra-abdominal infections.